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Abstract
Background: Huntington disease (HD) is an adult onset neurodegenerative disorder caused by a
polyglutamine expansion in the huntingtin (htt) protein. Htt function is essential for embryonic
survival as well as normal function during the postnatal period. In addition to having roles in
transcription and transport, recent evidence demonstrates that wild-type htt is neuroprotective in
vivo. To determine whether treatment with wild-type htt would be beneficial in HD, we crossed
the YAC128 mouse model of HD with mice that over-express wild-type htt (YAC18 mice) to
generate YAC128 mice that over-express wild-type htt (YAC18/128 mice).
Results: YAC18/128 mice were found to express mutant htt at the same level as YAC128 mice
and wild-type htt at the same level as YAC18 mice. YAC18/128 mice show no significant
behavioural improvement compared to YAC128 mice in the rotarod test of motor coordination
or in an automated open field test. In the brain, YAC18/128 mice show no significant improvement
in striatal volume, striatal neuronal numbers or striatal DARPP-32 expression compared to
YAC128 mice. In contrast, striatal neuronal cross-sectional area showed significant improvement
in YAC18/128 mice compared to YAC128 mice.
Conclusion: While the over-expression of wild-type htt results in a mild improvement in striatal
neuropathology in YAC128 mice, our findings suggest that treatment with wild-type htt may not
be sufficient to ameliorate the symptoms of HD in this model.
Background
Huntington disease (HD) is an autosomal dominant dis-
order resulting from a trinucleotide CAG expansion in the
HD gene. While the expression of mutant htt is sufficient
to cause HD-like symptoms with normal expression levels
of wild-type htt [1-3], recent data suggests that decreased
levels of wild-type htt in HD patients may also contribute
significantly to the pathogenesis of HD [4]. In support of
this, we have recently demonstrated that the loss of wild-
type htt in YAC128 mice significantly worsens motor per-
formance, survival and striatal neuronal size [5].
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Htt function is essential for development as mice
homozygous for the targeted inactivation of the mouse
HD gene are embryonic lethal [6-8]. Furthermore,
decreasing htt levels by 50% or more from birth results in
neurological abnormalities [7,9,10]. The expression of
wild-type htt is also essential postnatally as mice express-
ing decreased levels of wild-type htt in the forebrain
beginning at postnatal day 5 were shown to have a pro-
gressive neurological phenotype [11]. Clearly, decreased
wild-type htt levels alone can lead to phenotypic abnor-
malities independent of mutant htt.
As the functions of wild-type htt become more clear, it
seems that one of the most critical functions for htt may
be in promoting neuronal survival. In vitro studies have
demonstrated that the over-expression of wild-type htt
protects cells against various insults including 3-nitropro-
prionic acid, a toxin which damages the striatum and has
been used to model HD [12]. It has also been shown that
over-expression of wild-type htt can specifically protect
against polyglutamine toxicity in vitro [13]. This finding
has been extended in vivo where increased expression of
wild-type htt eliminated apoptotic degeneration in the
testis caused by the expression of mutant htt [5,14]. The
mechanism by which htt protects neurons may be direct
by sequestration of the pro-apoptotic protein HIP-1 [15]
or indirectly mediated through htt's effect on expression
and transport within the cell as htt has been shown to be
involved in both the transcription and movement of the
brain derived neurotrophic factor [16-18]. In contrast,
fragments of mutant htt have been shown to also protect
against some forms of injury (excitotoxicity) through a
different mechanism, likely the induction of a stress
response [19].
In HD, there is evidence that striatal neurons die through
excitotoxic mechanisms [20,21]. As such, we have previ-
ously examined the ability of htt to protect neurons in vivo
against two different excitotoxic neurotoxins. For these
experiments, we used YAC18 mice that over-express htt
from a yeast artificial chromosome containing the entire
human HD gene with 18 CAG repeats [22]. After intra-
peritoneal injection of kainic acid, YAC18 mice showed
dramatically less neuronal loss in the hippocampus com-
pared to WT controls [42]. Similarly, YAC18 mice showed
significant, htt dose-dependent protection against lesions
caused by intrastriatal injection of quinolinic acid [23].
Based on the clear demonstration of in vivo protection
against excitotoxic cell death in YAC18 mice and the gen-
eral protective effect of wild-type htt that has been demon-
strated in vitro, we designed this experiment to determine
if the over-expression of wild-type htt would be beneficial
in treating HD. Since HD patients have at least a 50%
genetic reduction in wild-type htt levels (resulting from
the presence of at least one copy of the mutant HD gene),
it is plausible that this decrease in htt's neuroprotective
function will make neurons more susceptible to the toxic-
ity of mutant htt. A decrease in wild-type htt levels may
also affect htt's role in transcription and transport within
the cell [16-18,24]. In fact many of htt's assayable func-
tions have been shown to be disrupted by polyglutamine
expansion [12,16,17,23] and polyglutamine expansion
also alters htt's ability to interact with its interacting pro-
teins [24]. Thus, treatment of HD with wild-type htt may
be beneficial by compensating for the loss of wild-type htt
function and or through htt's general neuroprotective
effect.
For this experiment we used the YAC128 mouse model of
HD which recapitulates many aspects of the human dis-
ease [3,25]. These mice exhibit progressive motor dysfunc-
tion, cognitive impairment and selective
neurodegeneration. YAC128 mice were crossed to YAC18
mice (which over-express full-length wild-type htt) to gen-
erate YAC128 mice that over-express wild-type htt
(YAC18/128 mice). We show that over-expression of
wild-type htt in YAC128 mice results in a mild improve-
ment in striatal neuropathology but does not improve
motor dysfunction.
Results
Generation of YAC128 mice that over-express wild-type 
huntingtin
To determine whether wild-type htt could protect against
mutant htt toxicity in the brain, we crossed YAC128 mice
with YAC18 mice to generate YAC128 mice that over-
express wild-type htt (YAC18/128 mice). In order to max-
imize the amount of neuroprotection imparted by over-
expression of wild-type htt, we used the highest expressing
YAC18 line (line 212) available. We have previously
shown that YAC18 line 212 mice express wild-type htt at
2–3 times endogenous levels [22,23,26] and exhibit the
greatest degree of neuroprotection against quinolinic acid
toxicity of all the YAC18 lines [23]. To confirm the high
expression of htt in line 212 mice, we examined total
wild-type huntingtin in line 212 and WT mice by Western
blotting with polyclonal bkp1 antibody [27]. As previ-
ously reported, we found that line 212 mice express wild-
type htt at levels that are more than two times the level of
wild-type htt expression in WT mice (Fig. 1A, (WT: 0.386
± 0.014 arbitrary units, YAC18: 0.942 ± 0.056 arbitrary
units, p = 0.02).
After breeding YAC18 and YAC128 mice together, YAC18/
128 mice were generated in equal proportions to WT,
YAC18 and YAC128 mice indicating normal embryonic
survival. Since the YAC transgenes used to generate YAC18
and YAC128 mice express human htt, we examined trans-
genic htt expression with the human specific htt antibody,BMC Neuroscience 2006, 7:80 http://www.biomedcentral.com/1471-2202/7/80
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HD650 (Fig. 1B; [3]). We also examined total htt expres-
sion using MAB2166 which detects both mouse and
human htt (Fig. 1B). As expected, WT mice (non-trans-
genic FVB/N) express wild-type mouse htt and no human
htt. YAC18 mice express increased levels of wild-type htt
which are accounted for by increased human htt expres-
sion. YAC128 mice express wild-type htt at the same level
as WT mice and human mutant htt. Finally, YAC18/128
mice express increased levels of wild-type htt and mutant
human htt. Importantly, the level of mutant htt expres-
sion was equal between the YAC128 and YAC18/128 mice
indicating that the over-expression of wild-type htt did
not down-regulate the expression of mutant htt (Fig. 1C;
YAC128: 3389 ± 197 arbitrary units, YAC18/128: 3303 ±
316 arbitrary units, p = 0.8; N = 3).
Over-expression of wild-type huntingtin does not improve 
motor function in YAC128 mice
To examine the effect of wild-type htt on the motor dys-
function present in the YAC128 mice, we monitored
motor coordination on the rotarod from 2 to 12 months
of age. While ANOVA revealed an overall effect of geno-
type on rotarod performance (genotype: F(3,36) = 7.9, p <
0.001, N = 8 WT, 9 YAC128, 16 YAC18, 8 YAC18/128),
there were no significant differences between the YAC128
mice and YAC18/128 at any time point (YAC128: 147 ±
13 seconds, YAC18/128: 134 ± 14 seconds, pYAC128vsYAC18/
128 = 0.5, YAC18: 164 ± 19 seconds). Both groups per-
formed significantly worse than WT mice (WT: 227 ± 15
seconds, p < 0.001).
We have previously reported early hyperactivity and late
hypoactivity in YAC128 mice compared to WT mice [3,5].
As such, we compared the activity of YAC18/128 mice and
YAC128 mice at 2 and 12 months of age to determine if
wild-type htt expression could ameliorate the abnormal
activity pattern present in YAC128 mice. We observed no
significant improvement in activity in YAC18/128 mice
compared to YAC128 mice (2 months – YAC128: 334 ±
13 beam breaks, YAC18/128: 320 ± 12 beam breaks,
pYAC128vsYAC18/128 = 0.5, YAC18: 324 ± 11 beam breaks; 12
months – YAC128: 274 ± 19 beam breaks, YAC18/128:
289 ± 15 beam breaks, pYAC128vsYAC18/128 = 0.5, YAC18:
277 ± 11; N = 8 WT, 9 YAC128, 16 YAC18, 8 YAC18/128).
Overall, increasing wild-type htt expression did not pro-
vide a significant behavioural benefit to YAC128 mice.
While this study was not powered to demonstrate signifi-
cant differences in survival, the number of YAC18/128
mice surviving to 12 months was similar to what we nor-
mally observe in YAC128 mice [Table 1; 12 month sur-
vival – WT males: 91%, YAC128 males: 73%, YAC18/128
males: 73% (8 of 11 mice), WT females: 90%, YAC128
females: 93%, YAC18/128 females: 100% (4 of 4 mice)].
Huntingtin expression in YAC18/128 mice Figure 1
Huntingtin expression in YAC18/128 mice. YAC18 and 
YAC128 mice were crossed to generate YAC18/128 mice. 
A. To confirm high levels of htt over-expression in YAC18, 
line 212 mice we performed Western blots on whole brain 
lysates. We found that line 212 mice have 2.4 times the levels 
of wild-type htt as WT mice (WT: 0.386 ± 0.014 arbitrary 
units, YAC18: 0.942 ± 0.056 arbitrary units, p = 0.02). B. 
Total htt and human htt levels were assessed by Western 
blotting with MAB2166 and HD650 antibody respectively. 
The human specific HD650 antibody was used to detect htt 
expressed from the YAC transgenes in YAC18, YAC128 and 
YAC18/128 mice. Western blots performed with HD650 
antibody indicate that YAC18/128 mice express both wild-
type htt and mutant htt from YAC transgenes. As expected 
WT mice express no human htt, YAC18 mice express only 
wild-type human htt and YAC128 mice express only mutant 
human htt. Examination of total htt levels with MAB2166 
antibody reveals that all mice express similar levels endog-
enous wild-type htt. C. Quantification of protein expression 
reveals that YAC18/128 mice express mutant htt at the same 
level as YAC128 mice (YAC128: 3389 ± 197 arbitrary units, 
YAC18/128: 3303 ± 316 arbitrary units, p = 0.8). N = 3 mice 
per group. Error bars indicate standard error of the mean. 
A.U. = arbitrary units.
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Mice surviving to 12 months of age were sacrificed and we
examined brain and testicular weight as these have been
shown to be decreased in YAC128 mice [3,5]. In both
cases, there was a significant difference between YAC128
and WT mice which was not improved by the over-expres-
sion of wild-type htt (Brain weight – WT: 403 ± 7 mg,
YAC18: 402 ± 4 mg, YAC128: 384 ± 4 mg, YAC18/128:
382 ± 3 mg, pYAC128vsYAC18/128 = 0.6, N = 17 WT, 17
YAC128, 14 YAC18, 17 YAC18/128; Testis weight – WT:
164 ± 5 mg, YAC18: 152 ± 7 mg, YAC128: 142 ± 5 mg,
YAC18/128: 123 ± 4 mg, pYAC128vsYAC18/128 = 0.01, N = 7
WT, 8 YAC128, 10 YAC18, 10 YAC18/128). Unexpect-
edly, the testicular weight in YAC18/128 mice was signif-
icantly less than in YAC128 mice and there was a trend
towards decreased testicular weight in YAC18 mice com-
pared to WT. This suggests the possibility that high levels
of htt expression may be detrimental in the testis.
Over-expression of wild-type huntingtin results in mild 
improvement in striatal neuropathology in YAC128 mice
YAC128 mice demonstrate clear striatal neuropathology
at 12 months of age with decreased striatal volume, stri-
atal neuronal loss, striatal neuronal atrophy and
decreased striatal DARPP-32 expression [3,28]. To deter-
mine whether the expression of wild-type htt could amel-
iorate these striatal phenotypes we examined the striata of
YAC18/128 mice. Comparing YAC18/128 mice and
YAC128 mice revealed no significant improvement in stri-
atal volume (Fig. 2A; YAC128: 11.3 ± 0.2 mm3, YAC18/
128: 11.6 ± 0.2 mm3, pYAC128vsYAC18/128 = 0.3, YAC18 =
12.5 ± 0.3 mm3; N = 17 WT, 17 YAC128, 14 YAC18, 17
YAC18/128), striatal neuronal numbers (Fig. 2B; YAC128:
1.56 ± 0.03 million neurons, YAC18/128: 1.59 ± 0.03 mil-
lion neurons, p = 0.4, YAC18: 1.64 ± 0.03 million neu-
rons; N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128)
or striatal DARPP-32 expression (Fig. 2C; YAC128: 828 ±
28 arbitrary units, YAC18/128: 868 ± 22 arbitrary units,
pYAC128vsYAC18/128 = 0.3, YAC18: 1012 ± 19 arbitrary units;
N = 10 WT, 12 YAC128, 10 YAC18, 8 YAC18/128) with
increased wild-type htt expression. In each case, YAC128
mice showed significant abnormalities compared to WT
mice. In contrast, increasing wild-type htt expression in
YAC128 mice resulted in a significant reduction in striatal
neuronal atrophy (Fig. 2D; YAC128: 96.2 ± 1.6 um2,
YAC18/128: 108 ± 1.9 um2, pYAC128vsYAC18/128 < 0.001,
YAC18: 110 ± 1.7 um2; N = 17 WT, 17 YAC128, 14
YAC18, 17 YAC18/128) with the striatal neuronal cross-
sectional area in YAC18/128 mice being almost restored
to wild-type (WT: 110 ± 3 um2, p = 0.6).
Discussion
Based on recent work demonstrating a neuroprotective
function of wild-type htt and suggestions that loss of wild-
type htt function contributes to HD pathogenesis, we
investigated the therapeutic potential of wild-type htt in
the YAC128 mouse model of HD. We found that over-
expression of wild-type htt in YAC128 mice resulted in a
mild improvement in striatal neuropathology with no sig-
nificant improvement in behavioural phenotypes.
The effect of over-expression of wild-type htt in YAC128
mice is summarized in table 2. A robust finding of this
study was that over-expression of wild-type htt in YAC128
mice restored striatal neuronal size. Similarly, we have
found that decreasing wild-type htt levels in YAC128 mice
results in decreased neuronal size [5]. Combined, these
results suggest that wild-type htt levels influence neuronal
size and suggest that loss of wild-type htt may contribute
to the striatal neuronal atrophy observed in HD. An alter-
nate possibility is that striatal neuronal size is more
responsive to mildly beneficial effects of treatments as this
measure has been shown to exhibit the most dramatic
improvements in therapeutic trials in mouse models of
HD [29-31]. The effect of wild-type htt on neuronal size
may be related to htt's ability to increase BDNF transcrip-
tion [17] and transport [16] since BDNF promotes the sur-
vival and differentiation of striatal neurons.
In contrast to the significant improvement in striatal neu-
ronal size, there was no significant effect of wild-type htt
Table 1: Effect of modulating wild-type huntingtin levels on survival in YAC128 mice.
Sex Genotype Deaths Total Mice Percent Surviving
Males WT 4 46 91%
YAC18/128 3 11 73%
YAC128 12 48 75%
YAC128-/- 11 15 27%
Females WT 5 42 88%
YAC18/128 0 4 100%
YAC128 5 66 92%
YAC128-/- 3 19 84%
YAC128-/- mice express mutant htt and no wild-type htt. YAC128 mice express mutant htt and 2 copies of wild-type htt. YAC18/128 express 
mutant htt and increased levels of wild-type htt.BMC Neuroscience 2006, 7:80 http://www.biomedcentral.com/1471-2202/7/80
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over-expression on open field activity, striatal volume,
striatal neuronal counts or striatal DARPP-32 levels in
YAC128 mice, despite a trend towards improvement. In
parallel with these experiments we examined the effect of
eliminating wild-type htt expression in YAC128 mice and
found that there was a trend towards decreased striatal
volume, striatal neuronal counts and striatal DARPP-32
expression which did not reach significance [5] (see Addi-
tional file 1 for summary). It is possible that the 12 month
time point chosen to assess neuropathology in these
experiments was too late in the disease process and that
differences in severity were masked by a ceiling effect or
that we have missed differences in the onset of striatal
neuropathology.
In our previous study we observed a significant increase of
both rotarod performance and survival when wild-type
htt levels were increased in YAC128 -/- mice to wild-type
levels [5]. In this experiment, we did not observe any fur-
ther improvement in either rotarod performance or sur-
vival with the over-expression of wild-type htt suggesting
that there may be ceiling effect for the amount that wild-
type htt can improve these outcome measures. While this
study did not have enough power to demonstrate a signif-
icant improvement in survival, the fact that the percentage
of mice surviving to 12 months was similar to YAC128
mice suggests that the over-expression of wild-type hunt-
ingtin does not have a dramatic effect on survival in
YAC128 mice. The survival deficit in the YAC128 and
Over-expression of wild-type htt results in mild improvements in striatal neuropathology in YAC128 mice Figure 2
Over-expression of wild-type htt results in mild improvements in striatal neuropathology in YAC128 mice. 
Comparison of striatal phenotypes between YAC128 and YAC18/128 mice revealed that over-expression of wild-type htt 
resulted in no significant change in striatal volume (panel A: YAC128: 11.3 ± 0.2 mm2, YAC18/128: 11.6 ± 0.2 mm2, p = 0.3), 
striatal neuronal counts (panel B: YAC128: 1.56 ± 0.03 million neurons, YAC18/128: 1.59 ± 0.03 million neurons, p = 0.4) or 
striatal DARPP-32 expression (panel C: YAC128: 828 ± 28 arbitrary units, YAC18/128: 868 ± 22 arbitrary units, p = 0.3). In 
contrast, over-expression of wild-type htt resulted in a significant improvement in striatal neuronal cross-sectional area (panel 
D: YAC128: 96.2 ± 1.6 um2, YAC18/128: 108 ± 1.9 um2, p < 0.001). For each outcome measure, YAC128 mice show a signifi-
cant deficit compared to WT mice. N = 17 WT, 17 YAC128, 14 YAC18, 17 YAC18/128 except for striatal DARPP-32 expres-
sion where N = 10 WT, 12 YAC128, 10 YAC18, 8 YAC18/128. Error bars show standard error of the mean. ** p < 0.01. *** 
p < 0.001.
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YAC18/128 mice were only observed in male mice thus
confirming our previous observations [5]. Unexpectedly,
we found that increasing wild-type huntingtin expression
in YAC128 mice resulted in further decreases in testicular
mass. Combined with a trend towards decreased testicular
mass in YAC18 mice, this suggests the possibility that
expression of htt beyond a certain threshold may result in
testicular atrophy which is exacerbated by the presence of
mutant htt. It is also possible that the human origin of the
over-expressed htt contributes to the testicular phenotype.
Unfortunately, we are not aware of a mouse model that
over-expresses wild-type mouse htt at high levels that
would permit testing of this hypothesis.
In this study, we used the YAC128 mouse model of HD
which transgenically expresses mutant huntingtin at
approximately 75% of endogenous levels [3]. These mice
have two intact copies of the wild-type HD gene and we
have previously shown that they express wild-type htt at
the same level as WT mice [5]. As such, YAC128 mice
express higher levels of wild-type htt protein than patients
with HD. The fact that the levels of wild-type htt are
already increased in YAC128 mice may diminish the ther-
apeutic benefit we observe in YAC18/128 mice by further
over-expressing wild-type htt. To more directly assess the
therapeutic benefit of wild-type htt in HD, one could
over-express mouse wild-type htt in a knockin mouse
model of HD to assess the effect of wild-type htt on early
disease phenotypes in these mice.
The results of this study are congruent with comparisons
of homozygous and heterozygous HD patients and HD
mouse models which suggest that mutant htt has a greater
influence on the disease phenotype than wild-type htt.
Examination of disease severity in patients homozygous
and heterozygous for mutations in the HD gene have
reported either no difference or that homozygous HD
patients are more severely affected [32-37]. Two inde-
pendent studies have also examined the phenotype of
mice that are homozygous for a targeted expansion of the
HD gene (HD knock-in mice). In both cases, homozygous
HD knock-in mice exhibited a more severe phenotype
than heterozygous HD knock-in mice, but the differences
were mild [38,39]. These studies suggest that mutant htt
maintains many of the critical functions of wild-type htt
as replacement of wild-type htt with mutant htt has only
a mild effect on phenotype. However, it has been shown
that polyglutamine expansion disrupts htt's neuroprotec-
tive function [12,23], at least part of htt's role in transcrip-
tion [17] and transport [16], and also affects the
interaction of htt with its interaction partners [24]. Since
increasing mutant htt expression alone is known to result
in a more severe phenotype in mice [40], it suggests that
the increase in phenotypic severity between heterozygous
and homozygous patients and animal models is mainly
caused by the increase in mutant htt levels which is in line
with our findings that increasing levels of wild-type htt
has only a small impact on the disease phenotype.
These findings are surprising given the importance of htt
function and its demonstrated neuroprotective abilities.
Htt is essential for embryonic development and decreases
in htt expression alone lead to abnormal phenotypes [6-
8,10,11,41]. Further, htt has been shown to protect cells
from death both in vitro and in the testis and in the brain
[12-14,23]. While htt has been shown to specifically pro-
tect against polyglutamine toxicity both in vitro [13] and
in the testis [5,14], our findings here indicate a milder
protective effect against mutant htt toxicity in the brain.
Given that wild-type htt exhibits protection against excito-
toxic neurotoxins [23], our finding that wild-type htt
mildly improves striatal neuropathology in YAC128 mice
is not inconsistent with excitotoxicity contributing to the
pathogenesis of HD.
Conclusion
Overall, our results demonstrate that the over-expression
of wild-type htt in YAC128 mice results in a mild
improvement in striatal neuropathology. Based on the
clear effect of htt over-expression on striatal neuronal size,
it appears that htt function may be important in maintain-
ing neuronal health. Despite the protective function of
Table 2: Effect of over-expression of wild-type huntingtin on HD-like phenotypes in the YAC128 mouse model of HD.
Phenotype Percent Difference 
YAC128 Compared to 
WT
Percent Difference 
YAC18/128 Compared 
to WT
Percent Rescue with 
WT htt Expression
Significance
Rotarod -36% -41% None p = 0.5
Activity – 2 Months +6% +2% 74% P = 0.5
Activity – 12 Months -10% -6% 47% P = 0.5
Striatal Volume -9% -7% 21% p = 0.3
Striatal Neuronal Counts -6% -3% 38% p = 0.4
Striatal DARPP-32 
Expression
-18% -14% 22% p = 0.3
Striatal Neuronal Size -12% -2% 87% p < 0.001BMC Neuroscience 2006, 7:80 http://www.biomedcentral.com/1471-2202/7/80
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wild-type htt, our results suggest that mutant htt toxicity is
primarily responsible for the pathognomic striatal neu-
ropathology in HD and that treatment of HD with wild-
type htt may not be sufficient to ameliorate the symptoms
of the disease.
Methods
Mice
YAC18 and YAC128 mice that express human wild-type or
mutant htt from a yeast artificial chromosome and wild-
type littermates were used for these experiments [3,22].
For YAC18 mice, we used the high-expressing line 212
which expresses wild-type htt at 2–3 times endogenous
levels [22]. Mice were maintained on the FVB/N (Charles
River, Wilmington, MA) background strain. Mice were
group housed with a normal light-dark cycle (lights on at
6:00 AM, lights off at 8:00 PM) in a clean facility and given
free access to food and water. All experiments were carried
out in accordance with protocols approved by the UBC
Committee on Animal Care and the Canadian Council on
Animal Care. The results shown are the combined results
from male and female mice. We examined the data for
both sexes separately and found no differences from the
combined results.
Behavioural analysis
Motor coordination was assessed on an accelerating
rotarod (UGO Basile, Comerio, Italy) as previously
described [5]. After training at 2 months, mice were tested
bimonthly from 2 to 12 months of age with a maximum
score for each trial of 300 seconds. Open field activity was
assessed in an automated open field apparatus (San Diego
Instruments, San Diego, California). Activity was meas-
ured at 2 months and at 12 months during a ten minute
open field trial. Activity was measured as the number of
beam crosses in the trial. Clean cages were used for each
trial. For behavioural assessment we used 8 WT (5 F, 3 M),
9 YAC128 (5 F, 4 M), 16 YAC18 (9 F, 7 M) and 8 YAC18/
128 (3 F, 5 M) mice.
Western blotting
Protein levels were measured from homogenized whole
brain lysates from a total of 3 mice per genotype. A low-
bis acrylamide gel was run with 100 μg of total protein per
sample for a total of 600 volt-hours. Proteins were trans-
ferred to a membrane at 24 volts for 1.5 hours. Blots were
then probed with antibodies for either total htt
(MAB2166, Chemicon, Temecula, California) or specifi-
cally human htt [HD650, (Slow et al., 2003a)] followed
by an anti-mouse, peroxidase-conjugated secondary anti-
body before enhanced chemiluminescent detection. Pro-
tein levels were quantified using Quantity One software
(Biorad, Hercules, CA).
Neuropathology
Neuropathology was carried out on 17 WT (11 F, 6 M), 17
YAC128 (10 F, 7 M), 14 YAC18 (8 F, 6 M) and 17 YAC18/
128 (8 F, 9 M) mice. Mice were perfused with 3% parafor-
maldehyde in phosphate buffered saline. Brains and testis
were post-fixed in 3% paraformaldehyde for 24 hours and
then equilibrated with PBS prior to weighing. Subse-
quently, brains were infiltrated with sucrose (25% in
PBS), frozen and sectioned on a cryostat (Microm HM 500
M, Richard-Allan Scientific, Calamazoo, Michigan).
A series of 25 μm coronal sections spaced 200 μm apart
were stained with NeuN primary antibody (1:100 dilution
in 5% NGS, 0.1% T-X-100, PBS; Chemicon) overnight at
room temperature, biotinylated anti-mouse secondary
antibody (1:200 dilution in 1% NGS, 0.1% T-X-100, PBS)
for 2 hours at room temperature and incubated in ABC
reagent (ABC Elite kit, Vector) for 2 hours at room temper-
ature before detection with metal-enhanced DAB solution
(Pierce, Rockford, Illinois).
Striatal volume was determined using Stereoinvestigator
software (Microbrightfield, Williston, Virginia). Briefly,
the perimeter of the striatum was traced using a 2.5X
objective in each section of the coronal series and the soft-
ware calculated the volume of the entire structure. Subse-
quently, neuronal profiles in a 25 μm × 25 μm counting
frame were counted with a 550 μm by 550 μm grid for all
grids the fell within the outlined areas. The counts were
then extrapolated to estimate the total number of neurons
in the striatum. To determine neuronal cross-sectional
areas, a single matched section from each animal was
stained with an Alexa488-conjugated NeuN antibody
(Chemicon). Mounted sections were analyzed using Ster-
eoinvestigator to outline the perimeter of all clearly
defined neurons within a 550 μm × 550 μm grid of 25 μm
× 25 μm counting frames with the 100X objective. On
average 32 neurons per mouse were assessed for a total of
more than 450 neurons per genotype.
For measurement of DARPP-32 expression, sections were
stained with rabbit anti-DARPP-32 antibody (Chemicon
AB 1656, 1:1000). After 3 washes with PBS, sections were
incubated in Cy3-conjugated goat anti-rabbit antibody
(1:500; Jackson ImmunoResearch Inc., West Grove, Penn-
sylvania). Pictures of mounted sections were taken using
MetaMorph Imaging System (Molecular Devices, Down-
ingtown, Pennsylvania) and the intensity of the fluores-
cent stain within the striatum was measured. 10 WT, 12
YAC128, 10 YAC18 and 8 YAC18/128 were used for this
analysis.
Immunohistochemistry for markers of neuronal health
was performed as described above using the following
antibodies: synaptophysin (1:100; BD Transduction Lab-BMC Neuroscience 2006, 7:80 http://www.biomedcentral.com/1471-2202/7/80
Page 8 of 9
(page number not for citation purposes)
oratories, Mississauga, Ontario), calbindin (1:2000; pro-
vided by Ken Bainbridge, University of British Columbia,
Canada), EM48 (1:500; provided by Xiao-Jiang Li, Emory
University, U.S.A) and 8-hydroxy-2-deoxyguanosine
(1:500; Japan Institute for the Control of Aging, Fukuroi
City, Japan).
Statistical analysis
Overall effects of genotype were determined by one way
ANOVA. Repeated measures ANOVA analysis was used for
analysis of differences in rotarod performance. The signif-
icance of differences between YAC128 and YAC18/128
mice was determined by either the Tukey post-hoc test fol-
lowing ANOVA or a student's t-test.
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